期刊文献+

消癌平联合奥宁治疗晚期卵巢癌65例临床观察 被引量:5

原文传递
导出
摘要 目的观察消癌平联合奥宁治疗卵巢癌的临床效果。方法65例晚期卵巢癌患者随机分为甲、乙两组,甲组(32例)给予消癌平联合奥宁治疗,乙组(33例)给予消癌平+化疗治疗。比较肿瘤组织生长抑素受体2(SSTR 2)和肿瘤标志物治疗前后的变化与疗效的关系。结果甲组32例,可观察的实体瘤治疗总有效率为37.5%,12例合并腹腔积液治疗总有效率为80%。乙组33例,患者的临床受益疗效(CBR)较高,SSTR 2表达与疗效比较符合率达71%(5/7),但肿瘤标志物治疗前后变化不显著。随诊结果除1例于休息阶段死亡外,其余均接受了再次治疗。结论消癌平-生长抑素类似物治疗难治性卵巢癌有确切疗效,合并应用化疗可使抗肿瘤作用获得互补。
作者 曹艳芳
出处 《临床医学》 CAS 2009年第1期71-73,共3页 Clinical Medicine
  • 相关文献

参考文献15

  • 1王世阆.难治性和复发性卵巢癌的治疗[J].实用医院临床杂志,2005,2(2):1-2. 被引量:2
  • 2周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,2005:601~610.
  • 3Buscail L, Saint - Laurent N, Chastre E, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer [ J ]. Cancer Res, 1996,56 ( 8 ) : 1823 - 1827.
  • 4Reisine T, Bell GI. Molecular properties of somatostatin receptors[J].Neuroscience, 1995,67 (4) :777 - 790.
  • 5Burghardt N, Barabas K, Marcsek Z, et al. Inhibitory effect of a long -acting somatostatin analogue on EGF - stimulated cell proliferation in Capan -2 cells[J]. J Physiol Paris,2000,94( 1 ) :57 -62.
  • 6Albini S, Florio T, Giunciuglio D, et al. Somatostatin controls kaposi's sarcoma tumor growth through inhibition of angiogencsis[J]. FASEB J,1999,13(6) :647 -655.
  • 7Zalatnai A, Pogany V. Apoptosis - induction and phosphorylation statein human pancreatic carcinoma xenografts following octreotide treatment [ J ]. Anticancer Res,2001,21 ( 1 ) :477 - 480.
  • 8刘文斌,李建生.生长抑素抗肿瘤机制研究进展[J].安徽医药,2005,9(1):7-9. 被引量:22
  • 9季字彬,张广美.中药抗肿瘤有效成分药理应用[M].哈尔滨:黑龙江科学技术出版社,1998:156.
  • 10张庆民,龚惠明.抗癌中药的临床应用【M】.北京:人民卫生出版社,1998:100.

二级参考文献27

  • 1萧树东,李德华,张德中,沈谋积,朱孝庭,栗原稔.应用ACNU与Me-CCNU联合化疗治疗进展期胃癌的随机研究[J].中华肿瘤杂志,1996,18(1):30-33. 被引量:3
  • 2[2]Alberts DS.Treatment of refractory and recurrent ovarian cancer [J].Semin Oncol, 1999,26(Suppl 1 ) :8 ~ 14.
  • 3[3]Schink JC. Current initial therapy of Stage Ⅲ and Ⅳ Ovarian cancer:Challenges for managed care[J ]. Semin Oncol, 1999,26(Suppl 1 ): 2~7.
  • 4[4]Ten Bokkell Huinink W.Gore M,Carmichael J,et al.Topotecan versus paclitaxel for the treatment of recurrent epithelial orarian cancer[J ]. J Clin Oncol, 1997,15(7) :2183 ~ 91.
  • 5Florio T,Thellung S, Corsaro A ,et al. Characterization of the intra cellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro [ J ]. Clin Endocrinol(Oxf) ,2003,59 ( 1 ): 115 - 28.
  • 6Cattaneo MG, Scita G, Vicentini LM. Somatostatin inhibits PDGF stimulated Ras activation in human neuroblastoma cells [ J ]. FEBS Lett, 1999,459 ( 1 ) :64 - 8.
  • 7Pola S,Cattaneo MG, Vicentini LM. Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity [ J ]. J Biol Chem, 2003,278 (42): 40601 - 6.
  • 8Douziech N, Calvo E, Coulombe Z, et al. Inhibitory and stimulatory effects of somatostatin two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-1 [J]. Endocrinology, 1999, 140(2) :765 -77.
  • 9Charland S,Boucher MJ,Houde M, et al. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/44 mitogen-activated protein(MAP) kinase activation in normal and tumoral pancreatic acinar cells [ J ]. Endocrinology,2001,142 ( 1 ): 121 - 8.
  • 10Sharma K, Patel YC, Srikand CB, et al. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3 [ J ]. Mole Endocrinology, 1996,10 (2): 1688 -96.

共引文献209

同被引文献67

引证文献5

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部